Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis

Yuri Ohshima-Terada, Yuki Higuchi, Takehisa Kumagai, Akihito Hagihara, Masahiko Nagata

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Atopic dermatitis is a common skin disease encountered in dogs. Glucocorticoids are commonly recommended for symptomatic therapy and well-tolerated adjunctive therapies may help to reduce the necessary dose and associated risks of chronic glucocorticoid use. Hypothesis/Objectives: The purpose of this study was to evaluate the complementary efficacy of oral administration of Lactobacillus paracasei K71 in canine atopic dermatitis (cAD). Animals: Forty one dogs with mild to moderate cAD were recruited by19 animal hospitals. Methods: Dogs were assigned to receive either the investigational agent (K71 group; n = 20) or cetirizine hydrochloride (control group; n = 21). Previously prescribed medications were allowed to be continued during the 12 week trial. Dogs were assessed by the investigators using the cAD Extent and Severity Index (CADESI) and a medication scoring system. Pet owners assessed their dogs using a visual analog scale (VAS) and pruritus scores. Results: The CADESI scores, VAS and pruritus scores in both groups at 12 weeks were improved compared with their baselines. The CADESI and pruritus scores in the K71 group were slightly lower than those in the control group and the reduction of medication scores in the K71 group was significantly lower compared with the control group (P < 0.05; Student's t-test). Conclusions and clinical importance: Oral administration of K71 can be useful in dogs with cAD as a complementary therapy, by providing a steroid-sparing effect.

Original languageEnglish
Pages (from-to)350-e75
JournalVeterinary Dermatology
Volume26
Issue number5
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Lactobacillus paracasei
atopic dermatitis
Atopic Dermatitis
oral administration
Oral Administration
Canidae
Dogs
dogs
Pruritus
pruritus
Visual Analog Scale
Control Groups
Glucocorticoids
drug therapy
Medication Systems
Cetirizine
Animal Hospitals
glucocorticoids
Pets
Complementary Therapies

All Science Journal Classification (ASJC) codes

  • veterinary(all)

Cite this

Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis. / Ohshima-Terada, Yuri; Higuchi, Yuki; Kumagai, Takehisa; Hagihara, Akihito; Nagata, Masahiko.

In: Veterinary Dermatology, Vol. 26, No. 5, 01.10.2015, p. 350-e75.

Research output: Contribution to journalArticle

Ohshima-Terada, Y, Higuchi, Y, Kumagai, T, Hagihara, A & Nagata, M 2015, 'Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis', Veterinary Dermatology, vol. 26, no. 5, pp. 350-e75. https://doi.org/10.1111/vde.12224
Ohshima-Terada, Yuri ; Higuchi, Yuki ; Kumagai, Takehisa ; Hagihara, Akihito ; Nagata, Masahiko. / Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis. In: Veterinary Dermatology. 2015 ; Vol. 26, No. 5. pp. 350-e75.
@article{52dbf38756ce4009ae1aac39e041ef43,
title = "Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis",
abstract = "Background: Atopic dermatitis is a common skin disease encountered in dogs. Glucocorticoids are commonly recommended for symptomatic therapy and well-tolerated adjunctive therapies may help to reduce the necessary dose and associated risks of chronic glucocorticoid use. Hypothesis/Objectives: The purpose of this study was to evaluate the complementary efficacy of oral administration of Lactobacillus paracasei K71 in canine atopic dermatitis (cAD). Animals: Forty one dogs with mild to moderate cAD were recruited by19 animal hospitals. Methods: Dogs were assigned to receive either the investigational agent (K71 group; n = 20) or cetirizine hydrochloride (control group; n = 21). Previously prescribed medications were allowed to be continued during the 12 week trial. Dogs were assessed by the investigators using the cAD Extent and Severity Index (CADESI) and a medication scoring system. Pet owners assessed their dogs using a visual analog scale (VAS) and pruritus scores. Results: The CADESI scores, VAS and pruritus scores in both groups at 12 weeks were improved compared with their baselines. The CADESI and pruritus scores in the K71 group were slightly lower than those in the control group and the reduction of medication scores in the K71 group was significantly lower compared with the control group (P < 0.05; Student's t-test). Conclusions and clinical importance: Oral administration of K71 can be useful in dogs with cAD as a complementary therapy, by providing a steroid-sparing effect.",
author = "Yuri Ohshima-Terada and Yuki Higuchi and Takehisa Kumagai and Akihito Hagihara and Masahiko Nagata",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/vde.12224",
language = "English",
volume = "26",
pages = "350--e75",
journal = "Veterinary Dermatology",
issn = "0959-4493",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis

AU - Ohshima-Terada, Yuri

AU - Higuchi, Yuki

AU - Kumagai, Takehisa

AU - Hagihara, Akihito

AU - Nagata, Masahiko

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: Atopic dermatitis is a common skin disease encountered in dogs. Glucocorticoids are commonly recommended for symptomatic therapy and well-tolerated adjunctive therapies may help to reduce the necessary dose and associated risks of chronic glucocorticoid use. Hypothesis/Objectives: The purpose of this study was to evaluate the complementary efficacy of oral administration of Lactobacillus paracasei K71 in canine atopic dermatitis (cAD). Animals: Forty one dogs with mild to moderate cAD were recruited by19 animal hospitals. Methods: Dogs were assigned to receive either the investigational agent (K71 group; n = 20) or cetirizine hydrochloride (control group; n = 21). Previously prescribed medications were allowed to be continued during the 12 week trial. Dogs were assessed by the investigators using the cAD Extent and Severity Index (CADESI) and a medication scoring system. Pet owners assessed their dogs using a visual analog scale (VAS) and pruritus scores. Results: The CADESI scores, VAS and pruritus scores in both groups at 12 weeks were improved compared with their baselines. The CADESI and pruritus scores in the K71 group were slightly lower than those in the control group and the reduction of medication scores in the K71 group was significantly lower compared with the control group (P < 0.05; Student's t-test). Conclusions and clinical importance: Oral administration of K71 can be useful in dogs with cAD as a complementary therapy, by providing a steroid-sparing effect.

AB - Background: Atopic dermatitis is a common skin disease encountered in dogs. Glucocorticoids are commonly recommended for symptomatic therapy and well-tolerated adjunctive therapies may help to reduce the necessary dose and associated risks of chronic glucocorticoid use. Hypothesis/Objectives: The purpose of this study was to evaluate the complementary efficacy of oral administration of Lactobacillus paracasei K71 in canine atopic dermatitis (cAD). Animals: Forty one dogs with mild to moderate cAD were recruited by19 animal hospitals. Methods: Dogs were assigned to receive either the investigational agent (K71 group; n = 20) or cetirizine hydrochloride (control group; n = 21). Previously prescribed medications were allowed to be continued during the 12 week trial. Dogs were assessed by the investigators using the cAD Extent and Severity Index (CADESI) and a medication scoring system. Pet owners assessed their dogs using a visual analog scale (VAS) and pruritus scores. Results: The CADESI scores, VAS and pruritus scores in both groups at 12 weeks were improved compared with their baselines. The CADESI and pruritus scores in the K71 group were slightly lower than those in the control group and the reduction of medication scores in the K71 group was significantly lower compared with the control group (P < 0.05; Student's t-test). Conclusions and clinical importance: Oral administration of K71 can be useful in dogs with cAD as a complementary therapy, by providing a steroid-sparing effect.

UR - http://www.scopus.com/inward/record.url?scp=84940792580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940792580&partnerID=8YFLogxK

U2 - 10.1111/vde.12224

DO - 10.1111/vde.12224

M3 - Article

C2 - 26123498

AN - SCOPUS:84940792580

VL - 26

SP - 350-e75

JO - Veterinary Dermatology

JF - Veterinary Dermatology

SN - 0959-4493

IS - 5

ER -